

REMARKS

In the present application, Claims 1-25 are pending and subject to a restriction requirement under 35 USC §121 and §372; Claims 9-11 and 14-17 are elected herein; and non-elected Claims 1-8, 12-13, and 18-25 are cancelled. Claim 9 is amended to recite the elected polypeptide sequence. Support for this amendment is provided in original Claim 9 and throughout the application. Therefore no new matter is presented by way of this amendment.

Responsive to the restriction requirement under 35 USC §121 and §372, applicant elects Group II (Claims 9-11 and 14-17) and the polypeptide sequence of SEQ ID NO: 20.

Applicant hereby expressly reserves the right under 35 U.S.C. §121 to file one or more divisional applications directed to the non-elected subject matter during the pendency of the present application.

Where helpful for facilitating the examination of this application, applicant encourages the Examiner to call the undersigned attorney at the telephone number provided below.

Respectfully submitted,
GENENTECH, INC.

Date: 13 July 2007

By: Anna Gil

Anna Gil
Reg. No. 46,726
Telephone No. (650) 225-1571